Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00251472 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer
A Phase 2 study of Metastatic Breast Cancer, sponsored by Veeda Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT00251472 is a Phase 2 study of Metastatic Breast Cancer that has completed, run by Veeda Oncology. The registered enrollment target is 72 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00251472, a Phase 2 study of Metastatic Breast Cancer, has completed, sponsored by Veeda Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase II, open-label, non-randomized study in patients with locally advanced or metastatic breast cancer. Each cycle of treatment will be 4 weeks in length. Patients will be radiologically evaluated every 8 weeks for response. Patients will continue to receive study treatment until disease progression or unacceptable toxicity.
Conditions Studied
Interventions
- DRUG Paclitaxel Albumin Nanoparticle for Injectable Suspension
Study Locations (1)
Ohio
- Veeda Oncology - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2005-03 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00251472
The ClinicalTrials.gov registry entry for NCT00251472 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (65% lower). The listed sponsor is Veeda Oncology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Paclitaxel Albumin Nanoparticle for Injectable Suspension is the first listed.
NCT00251472 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00251472 about?
NCT00251472 is a clinical study titled "A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer". This is a Phase II, open-label, non-randomized study in patients with locally advanced or metastatic breast cancer. Each cycle of treatment will be 4 weeks in length. Patients will be radiologically evaluated every 8 weeks for response. Patients will continue to receive study treatment until diseas...
What is the current status of trial NCT00251472?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2005-03. Estimated completion is 2010-05.
What conditions does trial NCT00251472 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT00251472?
The interventions under investigation include: Paclitaxel Albumin Nanoparticle for Injectable Suspension (DRUG).
Who is sponsoring clinical trial NCT00251472?
This trial is sponsored by Veeda Oncology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00251472 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.